LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

31.15

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

31.14

Máximo

31.18

Métricas clave
By Trading Economics
Ingresos	11M 64M
Ventas	-3.2M 149M
P/B Media del Sector	18.542 51.415
BPA	0.68
Margen de beneficios	42.663
Empleados	182
EBITDA	-7.8M 73M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+6.29% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	271M 3.8B
Apertura anterior	31.15
Cierre anterior	31.15

Noticias sobre sentimiento de mercado

By Acuity

37%

63%

118 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 may 2026, 22:54 UTC

Ganancias

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 may 2026, 23:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 may 2026, 23:51 UTC

Charlas de Mercado

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 may 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 may 2026, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 may 2026, 23:17 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 may 2026, 23:16 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 may 2026, 23:15 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 may 2026, 23:14 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 may 2026, 23:02 UTC

Charlas de Mercado

Ganancias

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 may 2026, 22:59 UTC

Charlas de Mercado

Ganancias

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 may 2026, 22:24 UTC

Ganancias

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 may 2026, 22:23 UTC

Ganancias

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 may 2026, 22:23 UTC

Ganancias

Xero FY International Revenue Growth 47%>XRO.AU

13 may 2026, 22:22 UTC

Ganancias

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 may 2026, 22:19 UTC

Ganancias

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 may 2026, 22:19 UTC

Ganancias

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 may 2026, 22:18 UTC

Ganancias

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 may 2026, 22:16 UTC

Ganancias

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 may 2026, 22:15 UTC

Ganancias

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 may 2026, 22:15 UTC

Ganancias

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 may 2026, 22:13 UTC

Ganancias

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 may 2026, 22:12 UTC

Ganancias

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 may 2026, 22:11 UTC

Ganancias

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 may 2026, 22:11 UTC

Ganancias

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 may 2026, 22:10 UTC

Ganancias

Xero Did Not Declare a Dividend>XRO.AU

13 may 2026, 22:10 UTC

Ganancias

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 may 2026, 22:09 UTC

Ganancias

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 may 2026, 22:00 UTC

Ganancias

Cisco to Shed Jobs for All-In AI Push -- Update

13 may 2026, 21:11 UTC

Ganancias

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

6.29% repunte

Estimación a 12 Meses

Media 33.1 USD 6.29%

Máximo 35 USD

Mínimo 31.5 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

118 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.